Questioning Medicine9 Apr 2024

Episode 266: 265. Semaglutide and Cardiovascular Events in Non-Diabetics (secondary prevention) SELECT TRIAL

The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis.

Improvement in

nonfatal stroke was not statistically significant

death from cardiovascular causes was no significant but

hold on it does appear nonfatal MI was significant and is what really drove the entire composite outcome

All the way down to the discussion to find “An important limitation of this trial is that we included only patients with preexisting cardiovascular disease. The effects of semaglutide on primary prevention of cardiovascular events in persons with overweight or obesity but without previous atherosclerotic disease were not studied. “

And that is because if you want to know the inclusion criteria you have to go to the supplementary data—

WHICH NO ONE DOES

This was sneaky and planned and terrible on the part of Novo Nordisk.

https://www.nejm.org/doi/10.1056/NEJMoa2307563?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(394)

Episode 432: 439. 6 articles in 2026

CME

24 Juli 25min

Episode 431: 438. CME- What To Do AFTER PE Diagnosis

OMED lecture

21 Juli 26min

Episode 430: edit fix 437. A Brief Review of the Medical Literature!

Xin X, et al. Optimal exercise modalities and dosages for blood pressure reduction in adults with prehypertension and established hypertension: A network meta-analysis and dose–response relationship s...

8 Juli 32min

Episode 429: 436. postpartum burnout., asundexian, semaglutide and ETOH, neck infection, varenicline

Jafari K, et al. Risk factors for pediatric deep neck infection revisit after emergency department discharge for pharyngitis or localized neck symptoms. Ann Emerg Med 2026 May; 87:605. DOI: 10.1016/j....

15 Juni 31min

Episode 428: 435. Evolocumab, Statin and CKD, PCN allergy, MRI vs Rotator Cuff

https://pubmed.ncbi.nlm.nih.gov/41903215/ Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV ...

8 Maj 17min

Episode 427: 434. 6 Articles From Arb to Patient Perspective to Cervical Cancer Screening

https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.70463 Angiotensin Receptor Blockers Versus Calcium Channel Blockers for First-Line Antihypertensive Therapy and Survival in Adults Aged 75Y...

4 Maj 25min

Episode 426: 433. Salt, Statins, and Stents

Donato J, et al. Things We Do For No Reason™: Low salt diets for patients with acute heart failure. J Hosp Med 2026 Feb 4; [e-pub]. DOI: 10.1002/jhm.70278.Some guidelines now recommend "normal sodium ...

21 Apr 16min